News

AB Science Secures EUR 2.8 Million Funding for Drug Development

AB Science Secures EUR 2.8 Million Funding for Drug Development

AB Science Successfully Completes a EUR 2.8 Million Funding Round

AB Science S.A. is thrilled to announce the successful completion of a capital increase amounting to EUR 2.8 million, achieved through a private placement with a select group of investors. This strategic move significantly boosts the company’s financial capabilities.

Funding to Propel AB8939 Clinical Trials

The funds raised from this private placement will primarily facilitate the company's ongoing activities, particularly focusing on the clinical development of the AB8939 program. AB8939 is a new synthetic drug designed to combat acute myeloid leukemia (AML). The immediate goal is to complete phase 1 in combination therapy while also launching an expansion study involving about 15 AML patients treated with AB8939 alongside Venetoclax, at the correct dosage.

Strategic Importance of the Expansion Phase

By entering the expansion phase, AB Science aims to gather robust preliminary evidence of efficacy in the AML indication, which is essential to support the subsequent registration trials. This targeted approach aligns well with the company’s vision of ensuring a higher chance of success for future registration studies.

Financial Position and Future Outlook

The completion of this funding round enhances AB Science’s cash position and provides the financial flexibility needed to address its operational expenditures throughout 2025 and beyond. This is a pivotal moment for the company as it strengthens its position in the pharmaceutical market, particularly within oncology.

Details of the Private Placement

The private placement involved the issuance of 2,477,877 new ordinary shares, each accompanied by a share warrant (BSA). This capital increase was conducted without the customary preferential subscription rights, a decision motivated by the urgency to expand operational capabilities swiftly. This move was sanctioned by the company’s board following the expressed will of the general meeting of shareholders.

Impact on Share Capital

With the completion of this capital increase, AB Science's total share capital will now amount to approximately EUR 729,474.72, translating into a fully diluted basis of share ownership, which ensures that existing shareholding structures are acknowledged during future transactions.

Cash Utilization Strategies

The net proceeds from this transaction are earmarked for funding critical activities. The company’s operational focus continues to hone in on the AB8939 clinical development program. By dedicating resources to this initiative, AB Science aspires to lead advancements in AML treatments that could benefit countless patients.

Future Trading of New Shares

The newly issued shares are set to be admitted to trading on the Paris regulated market. This trading is anticipated to start shortly, showcasing the company’s growing presence in the biotechnology sector.

Commitments and Timelines

As part of the funding agreement, the company has entered a lock-up period, ensuring investors are committed for at least 45 days post-transaction. This commitment reflects confidence in the company’s direction and the strategic decisions made by its leadership team.

About AB Science

Founded in 2001, AB Science specializes in the research and development of protein kinase inhibitors (PKIs). The company focuses on addressing high unmet medical needs in various fields, including oncology and inflammatory diseases. Noteworthy is the company's lead candidate, masitinib, which has established a track record within veterinary medicine and is making significant strides in human medical applications.

Prospects for Masitinib and AB8939

Masitinib represents a breakthrough in immunotherapy, designed to enhance patient survival outcomes, either alone or in conjunction with conventional chemotherapy. Similarly, AB8939 is being developed to overcome drug resistance, presenting new opportunities in oncology treatment landscapes.

Frequently Asked Questions

What is the purpose of the EUR 2.8 million raised?

The funds will primarily support the ongoing clinical development of the AB8939 program, particularly for AML treatments.

How will this funding affect the company’s operations?

The funding enhances AB Science’s financial stability and allows the company to advance its clinical trials and other operational activities effectively.

When will the new shares be available for trading?

The new shares are expected to start trading on the Paris regulated market soon, as part of standard operational procedures following the private placement.

What are the main goals of the AB8939 development program?

The main goals include completing phase 1 trials and initiating an expansion study to gather data supporting future registration for AML treatments.

What is the significance of the private placement for AB Science?

This private placement represents a critical step forward for AB Science, offering the necessary capital to pursue its strategic initiatives in treating significant medicinal conditions.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

OREF Opens $185,000 Research Grant Funding Cycle Today

Updated Category News Views 97

A hundred grand aimed at better graft science is not pocket change, but it is not a finished clinical program either. That distinction matters with the Orthopaedic Research and Education Foundation's newly opened $185,000 grant cycle. This is targeted, early-to-midstream research support: the sort of money that can produce usable data, sharpen a clinical question, and...

Continue Reading
Palm Beach Loan Company Tests Luxury Lending Demand

Updated Category News Views 103

Jewelry in a safe is dead capital until somebody lends against it. That plain fact sits behind Luxury Asset Capital's latest move: the launch of Palm Beach Loan Company, a South Florida brand aimed at wealthy owners of watches, diamonds, art, handbags, gold, collectibles, and other high-value possessions. The company is not asking clients to sell the stuff they spent...

Continue Reading
Dolby's Strong Quarter Meets a Flat 2027 Reality Check

Updated Category News Views 67

A licensing machine just coughed up a very good quarter, then told investors not to expect the engine to accelerate next year. That is the whole Dolby story in one uncomfortable breath. NYSE:DLB finished fiscal 2026 with fourth-quarter revenue of $374 million, up from $307 million a year earlier, while GAAP diluted earnings climbed to $0.86 from $0.51. Those are not...

Continue Reading
Vusion Lands a 2,000-Store dm EdgeSense Rollout in Germany

Updated Category News Views 10

A drugstore shelf rarely gets anyone's pulse racing, but 2,000 of them wired into a live digital system is a serious retail deployment. Vusion has expanded its partnership with dm-drogerie markt to roll out its newest EdgeSense platform across about 2,000 German stores over the next three years. This is not a glossy one-store pilot with a ribbon-cutting and a few tablets...

Continue Reading
LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 72

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 131

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
Visa Direct Tests Stablecoin Prefunding in Asia-Pacific

Updated Category News Views 71

Cross-border payouts have always had an ugly little problem: money can move digitally in theory, then sit around waiting for banks to wake up in practice. Triple-A’s new collaboration with Visa Direct aims straight at that nuisance in Asia-Pacific, allowing eligible clients to use stablecoins to prefund cross-border payouts while the recipient still gets local currency....

Continue Reading
Clorox Boosts Payout With Steady $1.25 Dividend

Updated Category News Views 152

Quarterly Dividends: A Clorox Tradition It seems you can't talk about Clorox (NYSE: CLX) without mentioning its steadfast dedication to shareholders. Once again, this 113-year-old stalwart is back on the map with its juicy quarterly dividend—$1.25 per share, to be precise. That's scheduled to hit your account by February 12, 2027, if you're on the books by the end of...

Continue Reading
Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 154

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 63

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading

Top 5 Most Recently Viewed Articles

ParagonX Holdings: Update on Company Transformation Plans

Updated Category News Views 146

ParagonX Holdings Shareholder Update ParagonX Holdings, Inc. (OTC:CAVR) recently shared insightful information regarding its transformation and strategic direction. The company is under the management of Caprino Management, LLC, which is actively assessing acquisition opportunities to bolster its growth. Divestitures and Debt Restructuring A significant step taken by...

Continue Reading
Applaud Receives Prestigious AI Award for Transforming HR

Updated Category News Views 300

Applaud Triumphs with Prestigious AI Award Applaud, a leading innovator in HR technology, has achieved significant recognition in the tech industry. The company’s generative-AI HR platform was awarded the flagship AI Award at a major international event. Applaud was selected among several finalists, showcasing its commitment to providing measurable value to employees...

Continue Reading
Empowering Stories: A Mother's Journey to a New Start

Updated Category News Views 257

Empowering Stories: A Mother's Journey to a New Start Anita's story is one of resilience. Faced with overwhelming challenges in her early life, she fought tirelessly to change her circumstances. Growing up without a family, she was married at a tender age to an older man, and for years, she juggled the responsibilities of motherhood while tending to her husband’s...

Continue Reading
First Capital REIT Declares Monthly Distribution for Investors

Updated Category News Views 176

First Capital REIT Announces Distribution for October 2025 First Capital REIT announces its cash distribution for October 2025, setting a notable precedent for its unitholders. The company has declared a distribution of $0.074167 per REIT unit, which translates to an annualized payout of $0.89 per unit. The payment is scheduled for November 17, 2025, to unitholders...

Continue Reading
Sidus Space and Other Major Stocks Experience Declines

Updated Category News Views 166

Stock Market Dynamics: Sidus Space and Others The U.S. stock market is seeing some fluctuations as futures showed little movement earlier today. Among these movements, Nasdaq 100 futures gently slipped by about 0.01%. In the midst of this, shares of Sidus Space, Inc. (NASDAQ: SIDU) are particularly noteworthy. Sidus Space's Price Adjustment Sidus Space recently made...

Continue Reading